Abstract Background: Race-related differences in breast cancer incidence and clinical outcome have been well documented, with many studies focusing on socioeconomic determinants contributing to African American (AA) breast cancer patients having higher mortality...
Multimodal approach to capture spatially resolved single-cell tumor heterogeneity in breast cancer
Abstract Tumor heterogeneity is known to play a key role in drug response and resistance. However, knowledge of tumor heterogeneity is largely limited to genetics and biopsy samples representing one region of the tumor. The study of spatial tumor heterogeneity is...
Novel imaging marker for low- and mid-recurrence score patients at risk for recurrence
Abstract Background: The 21-gene (Oncotype DX) recurrence score (RS) has been utilized as a prognostic assay in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The results stratify patients into...
Prediction of Response to Neoadjuvant Therapy (NAT) in Early Breast Cancer (EBC) at Community Hospitals – SimBioSys® TumorScope(TM) Validation Study
Abstract While most cancer patients are treated at community hospitals, specialized equipment, diagnostic tests, and therapeutic regimens are generally validated at academic settings. Here we present a novel approach to precision medicine to improve outcomes in breast...
The case for simul-omics: identifying IO biomarkers of Ganitumab-Metformin pathological complete response (pCR)
Abstract Background: During the I-SPY2 clinical trial, ganitumab (G) immunotherapy (IO) was co-administered with metformin (GM) to counteract G-induced hyperglycemia. The GM + standard of care (SOC) combination showed promising results but did not meet the statistical...